Mon Sep 16 15:16:00 UTC 2024: ## Law Firm Investigates Potential Misconduct at AlloVir, Inc.
**New York, NY (September 16, 2024) -** Kuehn Law, PLLC, a shareholder litigation firm, announced today that it is investigating potential breaches of fiduciary duty by officers and directors of AlloVir, Inc. (NASDAQ: ALVR). The investigation stems from a federal securities lawsuit alleging that AlloVir misled investors about the prospects of its posoleucel Phase 3 Studies.
The lawsuit claims that AlloVir insiders knew the studies were unlikely to meet their primary endpoints and that the company would likely discontinue them. Despite this, the company allegedly overstated the efficacy and clinical/commercial prospects of posoleucel, leading to materially false and misleading public statements.
Kuehn Law is encouraging AlloVir shareholders who purchased shares prior to January 11, 2023 to contact the firm. They are offering free consultations with no obligation and cover all case costs.
“Shareholders have a right to accurate information,” said Justin Kuehn, Esq., attorney at Kuehn Law. “By participating in this investigation, investors can help ensure the integrity and fairness of the financial markets.”
The firm emphasizes that time is of the essence for shareholders to exercise their rights, as there may be limited time to act.
**About Kuehn Law, PLLC:**
Kuehn Law, PLLC is a shareholder litigation law firm dedicated to protecting the rights of investors. The firm has a proven track record of successfully representing clients in complex securities class actions and derivative litigation.
First Piper 